Overall impact
C (55)

Commentary

Pfizer is an average overall performer. With a 'C' rating of 55.4 for overall impact (53rd percentile compared to all companies), Pfizer ranks 198th out of 245 industry peers, behind Catalyst Pharmaceuticals, Agios Pharmaceuticals, Pharmaron Beijing H and 194 others, and ahead of Akorn, PPD Incorporated, Azurity Pharmaceuticals and 44 others. On top material causes for Pfizer's industry (Pharmaceuticals), Pfizer performs well in Child and Maternal Health (92.7 score), Child and Maternal Health (83.8), Reduced Waste (86.8) and 24 other causes where it received an 'A' score and performs poorly in Humane Treatment of Animals (2.9 score), Accountable Institutions (12.3), Child and Maternal Health (30.7) and 36 other causes where it received a 'D' or 'F' score.
Impact
Cause PFE
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1849
Employees
81,000
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ny, United States
Share classes
PFE
Mission
Working together for a healthier world
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Material causes
Ethos considers the following causes material for Pfizer, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.